Comments
Loading...
Vincerx Pharma Analyst Ratings and Price Targets | OTC:VINC | Benzinga
Vincerx Pharma Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Vincerx Pharma Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Leerink Partners
Chardan Capital
SVB Leerink
B. Riley Securities
1calculated from analyst ratings
Analyst Ratings for Vincerx Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 10/08/2024 | Buy Now | — | Leerink Partners | Jonathan Chang39% | $80 → $40 | Maintains | Outperform | Get Alert |
| 04/09/2024 | Buy Now | — | Cantor Fitzgerald | Li Watsek40% | — | Reiterates | → Overweight | Get Alert |
| 04/01/2024 | Buy Now | — | Cantor Fitzgerald | Li Watsek40% | — | Reiterates | → Overweight | Get Alert |
| 09/07/2023 | Buy Now | — | Cantor Fitzgerald | Li Watsek40% | → $100 | Reiterates | Overweight → Overweight | Get Alert |
| 11/17/2022 | Buy Now | — | Chardan Capital | Matthew Barcus56% | $80 → $60 | Maintains | Buy | Get Alert |
| 08/12/2022 | Buy Now | — | SVB Leerink | Jonathan Chang39% | $120 → $100 | Maintains | Outperform | Get Alert |
| 06/08/2022 | Buy Now | — | Cantor Fitzgerald | Li Watsek40% | $440 → $160 | Maintains | Overweight | Get Alert |
| 06/07/2022 | Buy Now | — | B. Riley Securities | Kalpit Patel41% | $240 → $120 | Maintains | Buy | Get Alert |
| 06/07/2022 | Buy Now | — | Chardan Capital | Matthew Barcus56% | $220 → $80 | Maintains | Buy | Get Alert |
| 06/07/2022 | Buy Now | — | SVB Leerink | Jonathan Chang39% | $380 → $120 | Maintains | Outperform | Get Alert |
| 05/13/2022 | Buy Now | — | Chardan Capital | Matthew Barcus56% | $280 → $220 | Maintains | Buy | Get Alert |
| 05/13/2022 | Buy Now | — | SVB Leerink | Jonathan Chang39% | $400 → $380 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Vincerx Pharma (VINC) stock?
The latest price target for Vincerx Pharma (OTCPK:VINC) was reported by Leerink Partners on October 8, 2024. The analyst firm set a price target for $2.00 expecting VINC to rise to within 12 months (a possible 3408.77% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vincerx Pharma (VINC)?
The latest analyst rating for Vincerx Pharma (OTCPK:VINC) was provided by Leerink Partners, and Vincerx Pharma maintained their outperform rating.
When was the last upgrade for Vincerx Pharma (VINC)?
There is no last upgrade for Vincerx Pharma
When was the last downgrade for Vincerx Pharma (VINC)?
There is no last downgrade for Vincerx Pharma.
When is the next analyst rating going to be posted or updated for Vincerx Pharma (VINC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vincerx Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vincerx Pharma was filed on October 8, 2024 so you should expect the next rating to be made available sometime around October 8, 2025.
Is the Analyst Rating Vincerx Pharma (VINC) correct?
While ratings are subjective and will change, the latest Vincerx Pharma (VINC) rating was a maintained with a price target of $4.00 to $2.00. The current price Vincerx Pharma (VINC) is trading at is $0.06, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
